Skip to main content

Table 3 Clinical response to rituximab according to STAT3 polymorphism genotypes

From: Genetic polymorphisms of STAT3 correlated with prognosis in diffuse large B-cell lymphoma patients treated with rituximab

Response Genotype p
  CC + GG CG  
All patients    
   CR 53(60.2) 34(43.6) 0.032
PR + PD + SD 35(39.8) 44(56.4)  
   OR 77(87.5) 66(84.6) 0.591
  PD + SD 11(12.5) 12(15.4)  
GCB subtype    
   CR 14(77.8) 8(72.7) 0.758
PR + PD + SD 4(22.2) 3(27.3)  
   OR 17(94.4) 11(100) 0.426
  PD + SD 1(5.6) 0(0)  
Non-GCB subtype    
   CR 32(57.1) 19(33.3) 0.011
PR + PD + SD 24(42.9) 38(66.7)  
   OR 46(82.1) 46(80.7) 0.844
  PD + SD 10(17.9) 11(19.3)